Project Grant SB1AI197360
Award Date 7/20/26
Completion Date 6/30/29
Dollars Obligated $1M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Chapel Hill, NC, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded Epicypher, Inc. $999,268 on August 21, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop DAF-SEQ, an amplification-compatible long-read sequencing chromatin accessibility profiling assay for primary immune cells. DAF-SEQ combines haplotype-phased sequence analysis with single-molecule and single-cell chromatin accessibility profiling, enabling researchers to resolve chromatin structure in...
- The National Institute of Allergy and Infectious Diseases awarded Partillion Bioscience Corp $306,865 on July 16, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop nanovial-based technologies for accelerated monoclonal antibody discovery and characterization. Partillion will engineer novel nanovial formulations to enable streptavidin-antigen complexes as detection agents, increasing the multiplexing capacity of single-cell antibody screening assays. The...
- The National Institute of General Medical Sciences, part of the Department of Health and Human Services National Institutes of Health, awarded $323,090 to Tektonyx Bio, Inc. on August 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859, Assistance Listing R43GM165195). Tektonyx Bio is developing a semi-synthetic organism platform for the production of next-generation protein therapeutics. The organism harbors two synthetic nucleotides that form an unnatural base...
- The National Center for Advancing Translational Sciences at the National Institutes of Health awarded $931,463 to Acousticabio, Inc. on August 1, 2026, under SBIR Phase II funding (CFDA 93.350) to develop microgel-based formulations enabling subcutaneous delivery of monoclonal antibodies at ultra-high concentrations. Monoclonal antibodies currently require intravenous administration because their structural complexity and poor stability make high-concentration formulation difficult. IV...
- The National Center for Advancing Translational Sciences (NCATS) awarded Syntr Health Technologies, Inc., $2,050,527 on September 25, 2025, under the NCATS program (CFDA 93.350) to automate an FDA-cleared CD-microfluidic platform for rapid tissue microsizing. Syntr Health will develop device automation for its SYNTRFUGE system and SYNTRFPU360 platform to streamline tissue processing and dissociation. The technology processes multiple tissue types—including kidney, liver, brain, and breast cancer...
- The National Institute of Allergy and Infectious Diseases awarded Biotherapeutics, Inc. $314,363 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop oral first-in-class small-molecule therapeutics targeting a novel immunometabolic pathway for multiple sclerosis treatment. Biotherapeutics, Inc., a clinical-stage biotechnology company headquartered in Blacksburg, Virginia, will conduct Phase I research validating the safety, efficacy, and...
- The National Science Foundation awarded Helix Acoustics, Inc. $304,948 on July 1, 2026, under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084) to develop a benchtop focused ultrasound transducer array for rapid DNA extraction. The project will create a DNA extraction platform using a focused ultrasound transducer array that performs simultaneous tissue homogenization and cell lysis in a compact, integrated system. The technology applies high-pressure focused ultrasound...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded Scribe Biosciences, Inc. a $300,000 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a high-throughput antibody discovery platform against cell membrane-bound proteins. Scribe Biosciences, a for-profit company specializing in microfluidics and biomedical engineering, will utilize its proprietary Microenvironment on Demand (MOD) technology to assemble over 100,000 single-cell...
- The National Institute of Allergy and Infectious Diseases awarded Vivid Bioinnovations, PBC $299,991 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a spatially resolved single-cell DNA sequencing platform for spatial genomics with application to HIV reservoir mapping. The recipient will develop the first commercially viable spatial genomics platform integrating hydrogel-based spatial barcoding, droplet microfluidics, and Bayesian...
- The National Center for Advancing Translational Sciences at the National Institutes of Health awarded Onca Bio, Inc. $697,696 on September 15, 2025, under CFDA 93.350 (National Center for Advancing Translational Sciences) to develop segmented in vitro translation (SIVT) technology for expanding peptide library diversity in mRNA display applications. Onca Bio will apply SIVT to overcome a key limitation in current mRNA display macrocycle libraries, which are constrained by fixed residues at two...